AzTrials
AzTrials

Advanced Squamous Non-Small Cell Lung CancerPhase 2CECYDENCT07418931

A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer

A Phase 2 study testing Cemiplimab 350 mg IV, Paclitaxel 200 mg/sqm IV and Carboplatin AUC 5 IVa in people with Advanced Squamous Non-Small Cell Lung Cancer, run by Gruppo Oncologico Italiano di Ricerca Clinica at 15 sites in Italy.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This is a multicenter phase II study enrolling treatment- naïve patients with metastatic or recurrent squamous carcinoma of the lung Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Cemiplimab 350 mg IV, Paclitaxel 200 mg/sqm IV and Carboplatin AUC 5 IVa
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
108 participants
Where
15 sitesItaly
Study dates
May 2026to Nov 2030
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Written informed consent and any locally required authorization obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations.
  • Age > 18 years at the time of study entry.
  • Histologically or cytologically (cell blocks only; smears are not acceptable) documented pulmonary squamous carcinoma.
  • Stage IV or recurrent disease according to the AJCC 8th edition Cancer Staging Manual.
  • Body weight > 30 kg
Show all 28Show fewer
  • No prior chemotherapy or treatment with another systemic anti-cancer agent for the metastatic disease.
  • Patients who have received prior neo-adjuvant, adjuvant chemotherapy or chemoradiotherapy with curative intent for non-metastatic disease must have experienced a treatment- free interval of at least 6 months from enrolment since the last chemotherapy or completion of chemoradiotherapy.
  • Patients who received prior anti-PD-(L)1 as adjuvant or neoadjuvant therapy at stage 3B /3C disease will be allowed if have experienced a treatment-free interval of at least 6 months from enrolment since the last immunotherapy dose.
  • Known PD-L1 tumor status as determined by an IHC assay performed by local laboratory on previously obtained archival tumor tissue or tissue obtained from a biopsy at screening.
  • No need for concomitant chest irradiation.
  • ECOG perforance status 0-1.
  • Life expectancy ≥12 weeks.
  • At least one lesion measurable according to RECIST v 1.1 outside of the CNS, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis > 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) and which is suitable for accurate repeated measurements.
  • Adequate hematologic function as evidenced by absolute neutrophil count (ANC) ≥1,500/μL, hemoglobin ≥ 9.0 g/dL (5.58 mmol/L), and platelet count ≥ 100,000/μl.
  • Adequate hepatic and renal function:
  • Total bilirubin ≤ 1.5 times the upper limit of normal (ULN).
  • ALT (SGPT), AST (SGOT) ≤ 2.5 x institutional upper limit of normal (< 5 x ULN if the liver has tumor involvment).
  • Serum creatinine ≤ 1.5 times the ULN or creatinine clearance ≥ 60 mL/min, calculated according to the standard Cockcroft and Gault formula.
  • The patient has adequate coagulation function as defined by International Normalized Ratio (INR) ≤ 1.5 and a partial thromboplastin time (PTT) (PTT/aPTT) < 1.5 x ULN.
  • Patients on full-dose anticoagulation must be on a stable dose (minimum duration 14 days) of oral anticoagulant or low molecular weight heparin (LMWH). If receiving warfarin, the patient must have an INR ≤ 3.0.
  • Female patients must have a negative pregnancy test and not be breast feeding prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:
  • Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments.
  • Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments and with LH and FSH levels in the post- menopausal range for the institution.
  • Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation
  • For female patients of childbearing potential, agreement (by patient and/or partner) to use a highly effective form of contraception that results in a low failure rate (< 1% per year) when used consistently and correctly, and to continue its use for 6 months after the last dose of chemotherapy or at least 4 months after the last dose of cemiplimab, whichever occurs last. Such methods include: combined (estrogen and progestogen containing) hormonal contraception, progestogen-only hormonal contraception associated with inhibition of ovulation together with another additional barrier method always containing a spermicide, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, and vasectomized partner (on the understanding that this is the only one partner during the whole study duration).
  • Male patients who are sexually active must be willing to use barrier contraceptives (i.e.; by use of condoms) during sex with all partners during treatment with chemotherapy and for at least 6 months after the last dose of chemotherapy or at least 4 months after the last dose of cemiplimab, whichever occurs last. Patients should refrain from donating sperm from the start of dosing until 6 months after discontinuing study treatment.
  • Ability to comply with the study protocol, in the investigator's judgment.

Who cannot join

  • Patients with a sensitizing mutation in the epidermal growth factor receptor (EGFR) gene, or with anaplastic lymphoma kinase (EML4-ALK) translocations or with ROS1 proto-oncogene receptor tyrosine kinase (ROS1) translocations. EGFR mutations, ALK and ROS1 translocations will be assessed in never- smoker patients
  • Symptomatic brain metastases or spinal cord compression (CT or MRI of the head is required within 4 weeks prior to registration) requiring immediate radiotherapy for palliation. Patients with asymptomatic CNS lesions are eligible, provided that all of the following criteria are met:
  • The patient has no history of intracranial haemorrhage, spinal cord haemorrhage or haemorrhagic intracranial lesions
  • At least 14 days between the end of stereotactic radiotherapy or whole brain radiotherapy and initiation of study treatment, or at least 28 days between neurosurgical resection and initiation of study treatment
  • The patient is on a dose of corticosteroids ≤ 10 mg of oral prednisone or equivalent; anticonvulsant therapy at a stable dose is permitted
  • Metastases are limited to the cerebellum or the supratentorial region (i.e., no metastases to the midbrain, pons, medulla or spinal cord)
Show all 56Show fewer
  • There is no evidence of interim progression between completion of CNS directed therapy (if administered) and initiation of study treatment.
  • History of leptomeningeal disease.
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures. Patients with indwelling catheters (e.g., Pleura-Cath) are allowed.
  • Uncontrolled or symptomatic hypercalcemia (ionized calcium > 1.5 mmol/L, calcium > 12 mg/dL or corrected calcium > ULN).
  • History of cardiac disease: congestive heart failure >NYHA class 2; active CAD (MI or acute coronary syndrome more than 12 months prior to study entry is allowed); cardiac arrythmias requiring anti-arrythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension.
  • Transient ischemic attack or stroke within 1 year
  • Active SARS- COV-2 infection.
  • Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C.
  • Participants with HBsAg positive who have controlled infection (serum HBV DNA PCR that is below the limit of detection and receiving anti-viral therapy for hepatitis B) are eligible. Participants with controlled infections must undergo periodic monitoring of HBV DNA. Participants must remain on anti-viral therapy for at least 6 months beyond the last dose of investigational study medication.
  • Participants with HBsAg negative but total HBcAb positive are permitted with the following requirements: If serum HBV DNA PCR is above the limit of detection at screening, initiate HBV antiviral therapy before study entry. If serum HBV DNA PCR is below the limit of detection, periodic monitoring of HBsAg must be performed.
  • Participants who are HCV Ab+ who have controlled infection (undetectable HCV RNA by PCR either spontaneously or in response to a successful prior course of anti-HCV therapy) are eligible.
  • Known positive serology for HIV. Participants with known controlled HIV infection (undetectable viral load on HIV RNA PCR) and CD4 count above 350 either spontaneously or on a stable antiviral regimen are eligible. For these participants monitoring will be performed per local standards.
  • Any infection requiring hospitalization or treatment with IV anti-infectives within 2 weeks of first dose of study medication
  • Significant traumatic injury or radiotherapy involving an extensive field within the last 4 weeks prior to first dose of study treatment or anticipation of the need for major surgery during study treatment. Palliative radiotherapy to a limited field is allowed if concluded at least 2 weeks prior enrolment.
  • Other malignancies (previous or current), except for adequately treated in situ carcinoma of the uterine cervix, basal or squamous cell carcinoma of the skin, localized prostate cancer surgically treated with curative intent or ductal carcinoma in situ treated surgically treated with curative intent or if previous malignancy was more than 5 years prior and there are no signs or symptoms of recurrence.
  • Major surgery (including open biopsy) within 28 days prior to first dose of protocol therapy.
  • Prior allogeneic stem cell or solid organ transplantation.
  • Patients with any underlying medical condition that might be aggravated by treatment or which cannot be controlled i.e. patients with active serious infection, uncontrolled diabetes mellitus, pericardial effusion.
  • Any concurrent chemotherapy, Investigational Product, biologic, or hormonal therapy for cancer treatment other than those in the present study. Concurrent use of hormonal therapy for non-cancer- related conditions (e.g., hormone replacement therapy) is acceptable.
  • Treatment with any other investigational agent within 30 days prior to starting study treatment, or concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
  • Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contra- indicates the use of an investigational drug or puts the patient at high risk for treatment- related complications
  • Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this criterion:
  • Patients with vitiligo or alopecia
  • Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
  • Any chronic skin condition that does not require systemic therapy. Patients without active disease in the last 5 years may be included but only after consultation with the study physician
  • psoriasis that does not require systemic treatment.
  • Patients with celiac disease controlled by diet alone.
  • History or active autoimmune neurologic paraneoplastic syndrome (e.g. non infectious encephalitis, Lambert- Eaton syndrome etc.) or any other immune-mediated paraneoplastic syndrome.
  • Patients with SIADH or ectopic ATCH production are allowed on the study.
  • Patient has received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP. Receipt of COVID-19 vaccination within 1 week of planned start of study medication or for which the planned COVID-19 vaccinations would not be completed 1 week prior to start of study medication
  • History of idiopathic pulmonary fibrosis, including pneumonitis, drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
  • Prior therapy for metastatic disease with any anti-PD-1, anti-PD-L1, or anti-PD-L2 agent and anti-CTL-A4 agent.
  • Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 [IL-2]) within 4 weeks or 5 drug elimination half-lives (whichever is longer) prior to initiation of study treatment.
  • Any condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of randomization. The following are exceptions to this criterion:
  • Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)
  • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
  • Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
  • History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator.
  • History of allergies or hypersensitivity to any study drugs or study drug components or excipient.
  • Any unresolved toxicity NCI CTCAE Grade ≥ 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria:
  • Patients with Grade ≥ 2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician.
  • Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with carboplatin, paclitaxel, gemcitabine or cemiplimab may be included only after consultation with the Study Physician.
  • Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
  • Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 6 months after last chemotherapy dose or at least 4 months after the last dose of cemiplimab, whichever occurs last. WOCBP and men who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 4 months after the last dose. Highly effective contraceptive measures include:
  • Stable use of combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation initiated 2 or more menstrual cycles prior to screening;
  • Intrauterine device; intrauterine hormone-releasing system;
  • Bilateral tubal occlusion/ligation;
  • Vasectomized partner (provided that the male vasectomized partner is the sole sexual partner of the WOCBP study participant and that the vasectomized partner has obtained medical assessment of surgical success for the procedure); and/or Sexual abstinence
  • Patients should refrain from donating sperm from the start of dosing until 6 months after discontinuing study treatment.
  • Patients should not donate blood whilst on this study.

Trial locations and contacts

15 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Carmelo Tibaldi, MD contact

+39 0583 055748

carmelo.tibaldi@uslnordovest.toscana.it

15 sites in 1 country

Italy15 sites

  • UOC Oncologia Medica IRCCS Azienda Ospedaliero-Universitaria Policlinico Sant'Orsola

    Bologna, BO, 40138

    Francesco Gelsomino, MD

  • UO Oncologia Clinica Azienda Ospedaliero-Universitaria di Ferrara, Arcispedale Sant' Anna

    Cona, FE, 44124

    Giuseppe Bronte, MD

  • SC Oncologia Azienda Ospedaliera Santa Croce e Carle di Cuneo

    Cuneo, CN, 12100

    Ida Colantonio, MD

  • UOC Oncologia Medica Ospedale Versilia

    Lido di Camaiore, LU, 55041

    Andrea Camerini, MD

  • UOC Oncologia Medica Ospedale San Luca

    Lucca, LU, 55100

    Carmelo Tibaldi, MD

  • SC Oncologia Medica Ospedale Carlo Poma, ASST Mantova

    Mantua, MN, 46100

    Matteo Brighenti, MD

  • SSD Gruppo di Patologia Toracica IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.

    Meldola, FC, 47014

    Angelo Delmonte, MD

  • UOC Oncologia Medica Azienda Ospedaliero-Universitaria di Parma

    Parma, PR, 43126

    Leonetti Alessandro, MD

  • SOD Oncopneumologia Azienda Ospedaliero Universitaria Pisana

    Pisa, PI, 56124

    Antonio Chella, MD

  • UOC Oncologia Medica Ospedale dell'Alta Val d'Elsa

    Poggibonsi, SI, 53036

    Paolo Petreni, MD

  • SOC Oncologia Medica Nuovo Ospedale Santo Stefano

    Prato, PO, 59100

    Daniele Pozzessere, MD

  • SC Oncologia Medica Provinciale Azienda USL IRCCS di Reggio Emilia

    Reggio Emilia, RE, 42123

    Francesca Zanelli, MD

  • UOC Oncologia Medica ASST Valle Olona - Ospedale di Saronno

    Saronno, VA, 21047

    Alessandro D'Aveni, MD

  • UOC di Oncologia Medica Azienda Ospedaliero Universitaria di Sassari Ospedale Civile SS. Annunziata

    Sassari, SS, 07100

    Alessio Aligi Cogoni, MD

  • SC di Oncologia Azienda Ospedaliera Santa Maria

    Terni, TR, 05100

    Cristina Zannori, MD

Other trials in Italy

About this study

Official title: A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer - CECYDE Study

This is a multicenter phase II study enrolling treatment- naïve patients with metastatic or recurrent squamous carcinoma of the lung

Read the detailed description

Patients will receive chemotherapy plus Cemiplimab according to the baseline CDA enzymatic activity measured baseline in plasma samples by spectrophotometric assay: Patients with low CDA activity (< 7.2 U/mg) will receive: Cisplatin 80 mg/sqm on day 1 + Gemcitabine 1200 mg/sqm on days 1 and 8 and Cemiplimab 350 mg on day 1 administered every 3 weeks for 4 cycles followed by Cemiplimab 350 mg every 3 weeks until disease progression or unacceptable toxicity or a maximum of 108 weeks; or of investigator's choice: Carboplatin AUC 5 day 1 + Gemcitabine 1000 mg/sqm on days 1 and 8 and Cemiplimab 350 mg on day 1 administered every 21 days for 4 cycles followed by Cemiplimab 350 mg every 3 weeks until disease progression or unacceptable toxicity or a maximum of 108 weeks Patients with high CDA activity (≥ 7.2 U/mg) will receive carboplatin at an area under the concentration-time curve of 6 mg/mL/min IV (day 1) + paclitaxel 200 mg/sqm on days 1 and Cemiplimab 350 mg on day 1 administered every 21 days for 4 cycles followed by Cemiplimab 350 mg every 3 weeks until disease progression or unacceptable toxicity or a maximum of 108 weeks.

Being tested
Cemiplimab 350 mg IV, Paclitaxel 200 mg/sqm IV, Carboplatin AUC 5 IVa, Cisplatin 80 mg/sqm IV, Gemcitabine 1000 mg/sqm a

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cemiplimab 350 mg IVDrug

    Over approximately 30 min +/- 10 min. Day 1 every 21 days

  • Paclitaxel 200 mg/sqm IVDrug

    Over approximately 180 min. Day 1 every 21 days

  • Carboplatin AUC 5 IVaDrug

    Over approximately 15-30 min. Day 1 every 21 days

  • Cisplatin 80 mg/sqm IVDrug

    Over approximately 20 min. Day 1 every 21 days

  • Gemcitabine 1000 mg/sqm aDrug

    Over approximately 30 min. Day 1 and 8 every 21 days

  • Carboplatin AUC 6 IVbDrug

    Over approximately 15-30 min. Day 1 every 21 days

  • Gemcitabine 1200 mg/sqm bDrug

    Over approximately 30 min. Day 1 and 8 every 21 days

Study groups in NCT07418931
Study groupRoleWhat they receive
CDA activity < 7.2 U/mgExperimentalPatients with low CDA activity (< 7.2 U/mg) will receive: Cisplatin 80 mg/sqm on day 1 + Gemcitabine 1200 mg/sqm on days 1 and 8 and Cemiplimab 350 mg on day 1 administered every 3 weeks for 4 cycles followed by Cemiplimab 350 mg every 3 weeks until disease progression or unacceptable toxicity or a maximum of 108 weeks
Receives: Drug: Cemiplimab 350 mg IV; Drug: Cisplatin 80 mg/sqm IV; Drug: Gemcitabine 1200 mg/sqm b
CDA activity ≥ 7.2 U/mgExperimentalPatients with high CDA activity (≥ 7.2 U/mg) will receive carboplatin at an area under the concentration-time curve of 6 mg/mL/min IV (day 1) + paclitaxel 200 mg/sqm on days 1 and Cemiplimab 350 mg on day 1 administered every 21 days for 4 cycles followed by Cemiplimab 350 mg every 3 weeks until disease progression or unacceptable toxicity or a maximum of 108 weeks
Receives: Drug: Cemiplimab 350 mg IV; Drug: Paclitaxel 200 mg/sqm IV; Drug: Carboplatin AUC 6 IVb
CDA activity < 7.2 U/mg (at investigator's choice)ExperimentalAt Investigator's choice: Carboplatin AUC 5 day 1 + Gemcitabine 1000 mg/sqm on days 1 and 8 every 21 days for 4 cycles plus Cemiplimab 350 mg every 3 weeks followed by Cemiplimab 350 mg every 3 weeks until disease progression or unacceptable toxicity or a maximum of 108 weeks
Receives: Drug: Cemiplimab 350 mg IV; Drug: Carboplatin AUC 5 IVa; Drug: Gemcitabine 1000 mg/sqm a

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The primary endpoint is the Overall Survival (OS)

    The OS will be measured from the date of registration to the date of death by any cause and will be analyzed as survival rate at 1 year.

    Measured: Four years

Secondary outcomes (9)

  1. Secondary outcomes

    Median OS that will be measured from the date of registration to the date of death by any cause.

    Measured: Four years

  2. Secondary Outcome

    Survival rate at 3 year and 5 years will be analysed

    Measured: Three and five years

  3. Secondary Outcome

    Progression Free Survival (PFS) that will be measured from the date of registration to the date of disease progression

    Measured: Four years

  4. Secondary Outcome

    Objective Response Rate (ORR) that will be defined as the sum of complete response (CR)+ partial response (PR), based on the Investigator's assessment according to standard RECIST 1.1 criteria. Patients with no tumor assessment after baseline will be classified as non-responders.

    Measured: Four years

  5. Secondary Outcome

    Median Duration of Response (DoR) that will be measured from the date of first radiological evidence PR or CR to the date of first evidence of PD, both based on the Investigator's assessment according to standard RECIST 1.1 criteria. Patients with no tumor assessment after baseline will be classified as non-responders

    Measured: Four years

  6. Secondary Outcome

    Time to tumor response (TTR) that will be defined as the time from the start of treatment to the first objective of tumor response.

    Measured: Four Years

  7. Secondary Outcome

    Disease control rate (DCR) that will be defined as the sum of complete response (CR) + partial response (PR) + stable disease (SD), based on the Investigator's assessment according to standard RECIST 1.1 criteria

    Measured: Four Years

  8. Secondary Outcome

    OS, PFS and ORR will be analysed by PD-L1 levels: < 1%; 1- 49%, ≥ 50%.

    Measured: Four Years

  9. Secondary Outcome

    Toxicity that will be based mainly on the frequency and severity of adverse events (all grades and grade 3-4); severity will be measured according to NCI Common terminology Criteria Adverse Event (CTCAE), version 5.0. The worst severity grade adverse event will be considered for each patient.

    Measured: Four Years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Feb 2026
  2. Study startMay 2026 (estimated)
  3. Primary completionMay 2028 (estimated)
  4. Study completionNov 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
108 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07418931
Sponsor's protocol ID
GOIRC-04-2024
Acronym
CECYDE
Status last verified
Jan 2026
First submitted
4 Feb 2026
Last updated
18 Feb 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Cemiplimab 350 mg IV, Paclitaxel 200 mg/sqm IV and Carboplatin AUC 5 IVa in people with Advanced Squamous Non-Small Cell Lung Cancer, run by Gruppo Oncologico Italiano di Ricerca Clinica at 15 sites in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 28 inclusion and 56 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 18 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 15 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Carmelo Tibaldi, MD (+39 0583 055748, carmelo.tibaldi@uslnordovest.toscana.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The primary endpoint is the Overall Survival (OS) (time frame: Four years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07418931.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in